Plus therapeutics reports fourth quarter and full year 2023 financial results and business highlights

Began enrollment of the 5 th of an anticipated 7 planned dosing cohorts for the respect-lm phase 1 dose escalation trial with rhenium ( 186 re) obisbemeda for leptomeningeal metastases (lm)
PSTV Ratings Summary
PSTV Quant Ranking